TY - JOUR
T1 - Targeting auto-antibodies for CIDP
T2 - hope and questions
AU - Rajabally, Yusuf A.
PY - 2024/10/1
Y1 - 2024/10/1
N2 - Despite the availability of evidence-based treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), their use frequently results in incomplete recovery.1 Intravenous immunoglobulins, plasma exchange, and corticosteroids might improve function in some, but not all, people with CIDP. No trials involving other agents have, to date, shown a benefit.2 Side-effect profiles, tolerability, logistics for intravenous infusions, and difficulties of long-term venous access are additional barriers to effective treatment for patients with CIDP.
AB - Despite the availability of evidence-based treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), their use frequently results in incomplete recovery.1 Intravenous immunoglobulins, plasma exchange, and corticosteroids might improve function in some, but not all, people with CIDP. No trials involving other agents have, to date, shown a benefit.2 Side-effect profiles, tolerability, logistics for intravenous infusions, and difficulties of long-term venous access are additional barriers to effective treatment for patients with CIDP.
UR - http://www.scopus.com/inward/record.url?scp=85204019347&partnerID=8YFLogxK
UR - https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00362-4/fulltext
U2 - 10.1016/S1474-4422(24)00362-4
DO - 10.1016/S1474-4422(24)00362-4
M3 - Correction
C2 - 39304248
AN - SCOPUS:85204019347
SN - 1474-4422
VL - 23
SP - 955
EP - 956
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 10
ER -